Drug Discovery - Research & Development

Pfizer receives EC approval for Hympavzi to treat haemophilia

Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or B with inhibitors in patients aged 12 years and above.

Isomorphic Labs receives $2.1bn for AI drug development

AI drug design and development company Isomorphic Labs has secured $2.1bn in Series B funding to expedite its transition from developing innovative AI models to deploying them on a larger scale.

GSK and SBP Group team up to advance bepirovirsen launch in China

GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.

ACROBiosystems upgrades HEK293 licence solution for R&D compliance

ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).

Construction begins on Novartis’ RLT centre in Texas, US

Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.

Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn

Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its focus on brain health and rare diseases.

Daiichi Sankyo and Waiv partner for ADC biomarkers

Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.

Halozyme and Oruka sign agreement for Hypercon technology

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics for the development of ORKA-001 using Hypercon Technology.

Citius raises $36.5m for Lymphir commercialisation

Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy.